Daraxonrasib (RMC-6236): Molecular Design Behind Multi-Selective RAS Recognition

2026.09.10

Daraxonrasib (RMC-6236): Molecular Design Behind Multi-Selective RAS Recognition

Daraxonrasib, formerly known as RMC-6236, has drawn attention for a design strategy that differs from many earlier RAS-targeted molecules.

Its structure was developed to recognize the active, GTP-bound state of RAS across multiple RAS variants. The published discovery program describes daraxonrasib as a noncovalent RAS(ON) multi-selective tri-complex inhibitor and reports that medicinal chemistry optimization focused on interactions with residues conserved across mutant and wild-type RAS isoforms.

That raises an interesting medicinal chemistry question:

How can one molecule maintain productive recognition across several RAS variants while retaining a defined binding mode?

The answer lies in the way daraxonrasib uses molecular shape, a partner protein and a broader protein interface together.

Daraxonrasib at a Glance

The published discovery study describes daraxonrasib as an orally bioavailable macrocyclic molecule occupying a composite pocket formed by CypA and the Switch I / Switch II regions of RAS(ON).

What Does “Multi-Selective” Mean Here?

The word multi-selective deserves some explanation.

In this program, the goal was to preserve useful molecular interactions across several RAS forms. Researchers focused on structural features that remain relatively conserved among different mutant and wild-type RAS isoforms.

This creates a broader recognition strategy than one built around a single mutation-specific residue.

A useful way to describe the design is:

Daraxonrasib searches for structural features that different RAS variants have in common.

That shared structural foundation helps explain how one molecular framework can engage more than one RAS variant while maintaining a specific interaction pattern.

CypA Creates More Room for Molecular Recognition

Cyclophilin A plays a central structural role.

When daraxonrasib associates with CypA and RAS, the proteins form a composite binding surface. The drug can interact with structural elements contributed by both proteins rather than being confined to the surface of RAS alone.

For medicinal chemists, that changes the available design space.

A larger interface allows several parts of the molecule to contribute at the same time:

hydrophobic contacts · hydrogen bonding · aromatic interactions · van der Waals contacts

The overall fit is built from multiple interactions working together.

This helps explain why daraxonrasib requires a relatively elaborate molecular architecture.

What the Structural Studies Reveal

Published structural analysis provides a closer look at how daraxonrasib engages the RAS interface.

Several parts of the molecule participate in the interaction network. Reported contacts include regions around the cyclopropyl group, thiazole, indole core and pyridine-containing portion of the molecule.

The RAS residues involved include Pro34, Ile36, Ala59, Gln61, Tyr64 and Met67, with a combination of hydrophobic interactions, hydrogen bonding, π–π stacking and van der Waals contacts described in the structural analysis.

The value of these observations is not in any single contact.

The interaction pattern is distributed across the molecule.

That makes the complete three-dimensional arrangement more informative than simply listing individual functional groups.

Why the Macrocyclic Architecture Matters

Daraxonrasib is classified as a Beyond-Rule-of-5 macrocyclic molecule.

A macrocyclic framework can hold several molecular regions in defined spatial relationships, which is particularly useful when a compound needs to engage a broad and irregular protein surface.

In daraxonrasib, structural regions such as the indole, thiazole, pyridine and substituted side chains work as parts of one organized molecular system.

Molecular Shape Becomes a Design Parameter

For a molecule working at a protein–protein interface, geometry carries real functional importance.

The macrocyclic framework influences:

• how individual groups are oriented;
• how the molecule sits within the CypA–RAS interface;
• which contacts can occur at the same time;
• how the overall binding geometry is maintained.

The useful unit of analysis is the whole molecular shape, not an isolated functional group.

This is one of the clearest lessons from the RMC-6236 molecular architecture.

A Different Way to Think About RAS Drug Design

Daraxonrasib also illustrates how the questions asked in RAS medicinal chemistry are changing.

A mutation-focused project may begin with a particular residue or structural pocket.

The daraxonrasib program adds another possibility: create or exploit a composite protein interface and then design a molecule around the geometry of that interface.

The design problem becomes broader:

Which combination of protein surfaces and molecular contacts can produce a stable and useful recognition pattern?

That concept extends beyond any one functional group or one RAS mutation.

For medicinal chemistry teams, it provides a useful example of how molecular architecture, partner proteins and conserved protein features can be brought together within the same design strategy.

Clinical Development Context

The molecule has also progressed beyond the discovery stage.

On August 26, 2026, the U.S. FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who had received at least one prior systemic therapy or were not candidates for multiagent systemic therapy.

For a technical discussion of RAS chemistry, the relevance of this milestone is straightforward: a molecular strategy based on RAS(ON) recognition and a CypA-assisted composite interface has progressed from structure-guided discovery into an approved pharmaceutical application.

No clinical performance claims are needed here. The regulatory milestone itself provides the practical context.

Conclusion

Daraxonrasib (RMC-6236) offers a useful case study in modern RAS medicinal chemistry.

Three features stand out:

Conserved RAS Recognition
CypA-Assisted Composite Binding
Three-Dimensional Macrocyclic Architecture

Together, they create a molecular framework capable of engaging several RAS variants through a defined interaction network.

The broader lesson is equally valuable:

For complex protein interfaces, molecular geometry can be just as important as the individual functional groups within the molecule.

Daraxonrasib shows how that principle can be applied to multi-selective RAS(ON) molecular design.

For scientific and pharmaceutical R&D information only. The content is intended for technical communication and does not constitute medical advice, prescribing guidance or an offer to sell any specific patented compound.